A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma
NCT00863174 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2019-05-03
Summary
Safety and bioequivalence of SPARC\_147709
Conditions
Interventions
- DRUG
-
SPARC147709
SPARC147709 injection
- DRUG
-
Reference147709
Reference147709 injection
Sponsors & Collaborators
-
Sun Pharma Advanced Research Company Limited
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2011-01-31
- Completion
- 2011-04-30
More Related Trials
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
NCT07250646 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma
NCT02182141 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
NCT00590187 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
NCT01043874 ·Status: COMPLETED ·Phase: PHASE4
-
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
NCT01605981 ·Status: WITHDRAWN ·Phase: PHASE4
-
Multiple Ascending Dose of BMS-911543
NCT01236352 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
NCT02124746 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
NCT01692366 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
NCT04679870 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
NCT00719836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
NCT05367401 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
NCT00123487 ·Status: COMPLETED ·Phase: PHASE3
-
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
NCT01773187 ·Status: TERMINATED ·Phase: PHASE3
-
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06118788 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
NCT04277637 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02013167 ·Status: TERMINATED ·Phase: PHASE3
-
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
NCT01677780 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT07107204 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
NCT00532389 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
NCT04398680 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
NCT00481247 ·Status: COMPLETED ·Phase: PHASE3
-
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
NCT00760877 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
NCT07317700 ·Status: RECRUITING ·Phase: PHASE3